ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter of 2021 Fiscal Year
ImmunoPrecise and Genmab enter into a technology partnership targeting infectious disease ImmunoPrecise and Litevax advance
ImmunoPrecise and Genmab enter into a technology partnership targeting infectious disease ImmunoPrecise and Litevax advance